-
- conference
- Posted 23 hours ago
17th Conference on “Evidence Based Management of Cancers in India- EBM 2019”
1 Mar in Mumbai, India -
- job
- Posted 22 hours ago
JRF/Associate Research Scientist - Computational medicinal chemistry
At Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India -
- job
- Posted 3 days ago
Technical/Sr. Technical Associate
At ColgatePalmolive in Mumbai, India -
- job
- Posted 1 week ago
Sales Representative I
At Medtronic in Jalandhar, India -
- job
- Posted 3 weeks ago
Analyst - EOHS
At ColgatePalmolive in Mumbai, India -
- job
- Posted 1 month ago
Freelance Medical Writer
At Cactus Global in Mumbai, India -
- job
- Posted 1 month ago
Managing Editor, Medical Writing Team
At Cactus Global in Mumbai, India -
- job
- Posted 1 month ago
Animal Care and Resource Center Facility Assistants
At Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India -
- job
- Posted 1 month ago
Project assistant position in metabolomics and mass spectrometry
At Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India -
- job
- Posted 1 month ago
Medical Editor: Inviting Freshers
At CACTUS in Mumbai, India -
- job
- Posted 1 month ago
Freelance Pharma/Regulatory Editor
At CACTUS in Mumbai, India -
- job
- Posted 1 month ago
Senior Scientist
At Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India -
- job
- Posted 1 month ago
Managing Editor
At Cactus Global in Mumbai, India -
- insight
- Posted 2 months ago
How Indian biotech is driving innovation
Bolstered by government support, a wealth of investment and an eager graduate workforce, the country’s biotechnology industry is booming. Anu Acharya was in her twenties when the human genome was first mapped in its entirety. In 2000, the young Indian entrepreneur was just breaking into the biotechnology arena with her first start-up — the genomics and bioinformatics company Ocimum Biosolutions in Hyderabad. She saw the Human Genome Project’s achievements as opening up a new world of possibilities in personalized medicine, informed by an individual’s genetic profile and predispositions — but at the time, the field of genomic medicine was dominated by Western science. “I wanted to make sure that India had its own voice heard in that,” Acharya says. So, a decade later, she launched her second biotech start-up — molecular-diagnostics company Mapmygenome, also in Hyderabad — to bring the personalized-medicine revolution to India’s diverse population. “Because, ultimately, when you’re making medicine precise, it has to be for specific individuals and populations rather than based on one population that has been studied.” Acharya is among India’s rapidly growing ranks of biotechnology entrepreneurs and start-ups that are riding a wave of government enthusiasm, free-flowing venture capital and growing demand from an increasingly wealthy population that wants better treatment options. These factors are helping to drive India’s biotechnology industry beyond its historical focus on unbranded generic drugs and into the innovation limelight. By the end of 2016, there were more than 1,000 biotechnology start-ups in India, and more than half of these had been established within the previous 5 years. Australia, by contrast, has 470 biotechnology companies and the United Kingdom 3,835. The biotechnology industry in India was valued at US$11 billion in 2016, and is forecast to grow to $100 billion by 2025. More than half of the biotechnology start-ups are in the medical arena — diagnostics, drugs and medical devices — but 14% are in agricultural biotechnology, 3% in bioindustry, 1% in bioinformatics and 18% in biotechnology services. India is already eyeing the prospect of its first biotechnology ‘unicorn’ — a start-up valued at more than $1 billion. The potential unicorn in question, Biocon in Bangalore, started in 1978 as an enzyme manufacturer but is now making a name for itself in the research and development of biological drugs for treating diabetes, cancer and autoimmune diseases. By March 2018, its revenue had topped $650 million. India has long been a global player in the manufacture of generics (unbranded versions of existing pharmaceutical products), accounting for 20% of global exports of generics and earning just over $17 billion from that market in 2017. So what has prompted the nation to move beyond such a lucrative comfort zone and into the more risky game of biotechnology innovation? Government support In 1986, with the encouragement of then-prime minister Rajiv Gandhi, India became one of the first countries in the world to have a government unit dedicated solely to biotechnology. The Department of Biotechnology started with a relatively modest budget of between 40 million and 60 million rupees ($557,000–835,000), growing exponentially to 24.1 billion rupees in 2018. In addition to establishing 17 Centres of Excellence in Biotechnology at institutes and universities around the country, the department has supported the creation of 8 biotechnology parks, or incubators, in cities such as Lucknow, Bangalore, Hyderabad, Chennai and Kerala. The aim of these parks is to provide facilities for scientists and small to medium-sized enterprises (SMEs), where they can develop and demonstrate their technologies and even build pilot plants. The hope is that this will speed up the commercialization process. The park staff also provide mentorship and guidance on issues such as intellectual property, business plans, proposals for clinical development and exit strategies. This support is helping to address some of the logistical challenges that have hampered industry in the past, says Tej Singh, a biophysicist at the All India Institute of Medical Sciences in New Delhi and president of the Biotech Research Society, India. “They created some sort of industrial regions in many areas, but there were issues like electricity, water [supply]; all these small things used to take time,” Singh says. “But the government has addressed these things nowadays; this current government particularly is very proactive.” The Department of Biotechnology has also supported biotechnology research infrastructure, including a high-resolution mass spectrometry facility in Mumbai, flow-cytometry, imaging and microarray facilities in Delhi, and animal-house facilities in five other regions. The jewel in the departmental crown, and the scheme that attracts the most attention, is the Biotechnology Industry Research Assistance Council (BIRAC). This is a not-for-profit, public-sector enterprise that was set up by the Department of Biotechnology in 2012 to “stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry, particularly start-ups and SMEs”. “The idea of forming BIRAC was to support the innovation ecosystem in India, and to nurture innovators from academia and industry to work independently or together,” says Shirshendu Mukherjee, mission director of the Program Management Unit at BIRAC. Mukherjee says India has always excelled at basic research but has faced challenges in translating that into commercial outcomes. BIRAC’s mission is therefore to “take innovation from the bench to the bedside, from the lab to the field, from the desk to the market”, he says. In just six years of existence, BIRAC has supported 316 start-ups, which have generated $125 million through 122 products and technologies, including a cattle-feed supplement, a new process to manufacture human albumin and immunoglobulin, microfluidics-based diagnostics and a rapid test for malaria. Its initiatives include ‘biotechnology ignition grants’ of up to 5 million rupees for start-ups and entrepreneurs to take a proof-of-concept through to the first major step on the path to commercialization. Another is a ‘glue grants’ scheme, which connects clinical-science departments with those for basic science in institutes and universities in the hope that this will encourage partnerships and collaborations. BIRAC has also joined forces with the Bill & Melinda Gates Foundation in Seattle, Washington, on the Grand Challenges India initiative to tackle global health and development problems. “I always call my Grand Challenges programme ‘in India, for India and beyond’,” says Mukherjee. “So we will do it in India, we will validate it in India, we will use it India, our citizens will use it, and then if it goes beyond India we are happy to do that.” Consumer demand A similar motivation is driving at least some of the scientists and entrepreneurs such as Acharya, who get into the biotech space because they feel that Western biotechnology isn’t necessarily addressing the needs of the Indian population. One example is Vivek Wadhwa, a technology entrepreneur at Harvard Law School in Cambridge, Massachusetts, and at Carnegie Mellon University’s College of Engineering at Silicon Valley, California, who has invested in Indian medical-diagnostics company HealthCube in New Delhi. “I did a big study on the pharmaceutical industry in India, and I concluded that Western companies were not addressing Indian disease because it wasn’t profitable enough for them,” Wadhwa says. But as the cost of technologies such as genome sequencing and medical sensors comes down, Wadhwa says, it has now become viable for Indian biotechnologists to harness these advances for the Indian market. And what a market India is for these innovations. The country’s population is 1.36 billion and rising, and health care is one of India’s fastest-growing sectors, driven by higher incomes and an increasing prevalence of lifestyle diseases, such as heart disease and stroke. By 2022, the health-care market in India is expected to be worth $372 billion. “People are finally realizing that the consumer, or the patient, actually has control over their own health,” says Acharya. The rising middle class wants better health and medical choices, and she says that’s one of the main drivers for investment in biotechnology research and development. For example, Biocon has developed the first recombinant insulin to be produced in India, and an antibody-based treatment for head and neck cancer. In 2017, Indian vaccine manufacturer Bharat Biotech in Hyderabad began the first clinical trials of its vaccine against the mosquito-borne virus chikungunya, which re-emerged in India in 2006 after 32 years and infected more than 1.4 million people. Another major driver of the biotechnology boom in India is the accessibility of funding, from both government and private industry. In one 2016 report on biotechnology, India ranked only 49th out of 54 countries. But it scored particularly highly on the availability of venture capital compared to countries such as the United Kingdom, Australia and Canada. Acharya says that some of the investors who have made their fortunes in manufacturing generic pharmaceuticals are now investing in biotechnology. She says much of the capital investment in early-stage biotechnology is coming from India, whereas investment in medical devices is flowing from Japan, China and the United States. But late-stage investment is still an issue. “A lot of early-stage start-ups are getting funded but I think the challenge is still the late stage,” she says. “It’s not just the first two to three years; it’s more how do you take it from start-up to scale-up? I think that’s the challenge in terms of getting to where we need to get in terms of biotechnology.” Human resources One thing India has plenty of is people. Recognizing that human capital can be a key resource for a nation not as well endowed financially as Western countries such as the United States or United Kingdom, the Department of Biotechnology implemented or supported various training initiatives. These include the Biotech Industrial Training Programme, set up in 1993 for recent graduates, and 12 Biotech Finishing Schools in Karnataka state to train Indian graduates and researchers in biotechnology. That programme “created a very large number of institutions or departments of biotechnology in institutions and also departments of bioinformatics”, says Singh. For example, in September, the state of Gujarat proposed India’s first university focused entirely on biotechnology. “A decade or so ago, India didn’t have the engineers or scientists it does today — it’s been graduating them in droves,” says Wadhwa. “It has millions of technologists who now just need to be connected to the medical practice and they can be solving great problems.” Singh notes that these graduates aren’t waiting for a job to walk up and tap them on the shoulder; they’re taking matters into their own hands. “Graduate students who come out in large numbers from Indian institutes of technology and institutes of management are not looking for jobs so much; they create small start-ups and then they grow very fast,” Singh says. Working in biotechnology in India does present its own unique set of challenges, says Acharya. “Some operational things that you never have to think about in the United States you have to plan more in India, because a lot of times we are still importing the reagents and things like that.” Red tape Although the government of India is enthusiastic about supporting the biotechnology industry, Acharya says the regulatory process for getting products approved could be more streamlined. In agricultural biotechnology, the government’s Genetic Engineering Appraisal Committee has been working to make it easier for companies to get approval for genetically modified crop field trials from state governments. The drug approvals process in India has hit some rough patches in recent years, and the authors of a 2017 World Health Organization report suggested that innovation there could be outpacing regulation. Even the government’s own National Biotechnology Development Strategy for 2015–20 acknowledges that timelines and regulatory steps for biotechnology drug approvals are not user-friendly. It has proposed reforms, including the establishment of regulatory departments that are fluent in good practice in the clinical, manufacturing and laboratory arenas. There are also concerns about the environmental impact of India’s pharmaceutical industry. An investigation in 2016 found “unprecedented” levels of pharmaceutical pollution in the water system of Hyderabad (C. Lübbert et al. Infection 45, 479–491; 2017), which is home to a significant proportion of biotech start-ups and generics manufacturers. However, as the US Food and Drug Administration reportedly steps up inspections of overseas pharmaceutical suppliers, environmental standards could be forced to improve. Despite the challenges, there is palpable excitement about what lies ahead. “Right now, we are seeing the beginnings of a revolution in biotechnology in India,” Wadhwa says. Acharya is still fired with the same enthusiasm that propelled her into biotechnology nearly two decades ago. “Any innovation in this space can actually impact lives,” she says. “That’s why I continue to be in it.” This article is part of the Nature Spotlight on Indian biotechnology, an editorially independent supplement. Advertisers have no influence over the content.
-
- job
- Posted 1 month ago
Senior Clinical Trainer
At EngenderHealth in Rājkot, India -
- job
- Posted 1 month ago
Scientific Manager
At GVK Biosciences in Hyderabad, India -
- job
- Posted 1 month ago
Research Associate
At GVK Biosciences in Hyderabad, India -
- job
- Posted 2 months ago
Faculty Positions at all levels
At INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IISER), BHOPAL in Bhopal, India -
- job
- Posted 2 months ago
Faculty Positions at the Department of Biological Sciences
At Tata Institute of Fundamental Research in Mumbai, India -
- insight
- Posted 4 months ago
India’s Commitment to Science Begins to Pay Off
Illustration by Michelle Thompson; Photos: Getty, Shutterstock A push to reverse its brain drain is providing the expertise to tackle its domestic problems. When Anil Koul told his friends that he would be moving to India to start working at a government research and development organization, most of the reactions were of disbelief, “even sympathy”, he says. “Some thought it was a crazy idea — moving from the world’s largest health-care giant to a governmental, bureaucratic set-up.” Koul took charge of the Institute of Microbial Technology (IMTECH), in the northern city of Chandigarh, in 2016, relocating from Johnson & Johnson in Belgium, where he was senior director and head of the respiratory diseases group. The move to IMTECH — a branch of India’s government-run Council of Scientific and Industrial Research — was atypical. Few scientists return to India after holding top positions abroad, and fewer still move into the less-lucrative public sector. The scientific landscape that Koul has returned to is vastly different from the one he left in 1998. India is now actively participating in and, in some cases, leading advances in pharmaceuticals, agriculture and energy. The country’s efforts in space exploration are a point of particular national pride. India is preparing for its second Moon mission in 2018 after a successful maiden Mars mission in 2014, and is spreading its wings in international astronomy collaborations. The country will host the third laboratory of the Laser Interferometer Gravitational-wave Observatory (LIGO) project in Hingoli, while the National Centre for Radio Astrophysics in Pune is working on the design of the ‘Telescope Manager’ — the central command system of the Square Kilometer Array. These could be signs that India is enjoying ‘brain gain’ — Indian researchers are returning to their country of birth with newly minted research skills gained while abroad. This is a far cry from the state of the country’s scientific sector 40 years ago, when entire cohorts of graduates from India’s research institutes left for US institutions in search of better economic and educational opportunities. “We are now in an era of globalization and international cooperation,” says immunologist Indira Nath, a member of the Indian National Science Academy. “Scientists going abroad is no longer a big issue.” To-do list But India still faces significant challenges. It is home to one-quarter of the world’s tuberculosis (TB) cases, and continues to be ravaged by mosquito-borne infections including malaria and dengue fever. Around 700 million Indians (56% of the country’s population) have no sanitation, 240 million have no access to electricity and 97 million lack clean drinking water. Natural disasters such as droughts, floods and storms — already common across Southeast Asia — are set to increase in frequency and ferocity as the world’s climate changes. It falls on publicly funded research to take the lead in finding solutions. Since India gained independence from British rule 70 years ago, every prime minister has emphasized the role of science in the country’s development. The current incumbent, Narendra Modi, told a meeting of leading Indian science officials in July that science, technology and innovation are the keys to the progress and prosperity of India and that the government aims to apply science to solve the country’s problems. As various policy initiatives make clear, India is betting on science to address its pressing challenges in energy, environmental protection, food, water, sanitation, health care and unemployment. To achieve this, the government is hoping to find more scientists like Koul, who sees his role as an “opportunity to address bigger social as well as scientific challenges”. This is a tall order, and there’s an elephant in the room. Government funding for Indian research and development has stagnated at around 0.85% of gross domestic product for more than a decade, compared with at least 3% invested by technologically advanced nations such as Denmark, Japan and Sweden. Koul is nonetheless optimistic, and has helped to forge a collaboration between IMTECH and Johnson & Johnson, announced in August. They will work in parallel on four new molecules as potential drug targets and explore shorter, safer and more-effective oral treatment regimens for various strains of TB. Biopharma strides Koul’s collaboration is well placed to take advantage of the success of India’s pharmaceutical industry. Building on the solid foundations of the country’s expertise in academic chemistry, major pharmaceutical companies have set up factories to make affordable generic antibiotics, vaccines, and diabetes and HIV medicines. This strength is paying dividends. According to Hyderabad-based Sathguru Management Consultants, India’s pharmaceutical industry was worth US$18.8 billion in 2010 and $41.1 billion in 2017, and is expected to expand to an estimated $72.4 billion in 2022. One-fifth of the world’s generic drugs are made in India, and around half of this manufacturing is based in Hyderabad. The production of generics has certainly helped the sector, but many people hope to see the country grow beyond manufacturing. “We now need to be recognized for new drugs that address unmet medical needs,” says Kiran Mazumdar-Shaw, managing director of biopharmaceutical company Biocon in Bangalore. The firm’s growing pipeline of biologics ranges from oral insulin for diabetes to monoclonal antibodies for use in cancer therapy. “There is incredible potential within India to become a powerhouse driving biopharma innovation in the Asian market,” says Vaz Narasimhan, himself a second-generation Indian American and chief executive of Novartis, a pharmaceutical company in Basel. The biopharma industry is increasingly looking for new types of talent, says Narasimhan. He gives the example of data analysts and mathematicians who he says are driving the next wave of medical innovation. Meenakshi Diwan works on a solar panel in India’s Odisha state in 2009 — then part of a burgeoning solar grid with a capacity of less than 10 MW. Now, India has a solar capacity of more than 6,000 MW.Credit: Abbie Trayler-Smith/PANOS Narasimhan’s confidence in Indian pharmaceutical development is significant. Most pharma companies have been reluctant to take on costly research and development to combat ‘poor-man’s diseases’ such as malaria and TB, says Soumya Swaminathan, one of India’s leading experts on TB. Swaminathan was appointed deputy director-general for programmes at the World Health Organization in October. She has led an effort to consolidate India’s fragmented TB research, previously supported by four separate institutions, under one umbrella organization — the IndiaTB Research Consortium. “These diseases are our problem,” she says. “And it is pointless expecting Western pharma companies to be interested in them.” When asked, Indian pharmaceutical companies say they are reluctant to take up research in these areas, citing a lack of government funding for early-stage research, and reams of red tape once a product reaches clinical trials. Pollution pains In April, a collaboration between researchers in Germany and Anil Dayakar, an environmental activist in India, reported that Hyderabad’s pharmaceutical manufacturing was polluting the region’s water system to an “unprecedented” degree, and hurrying the development of drug-resistant forms of bacteria (C. Lübbert et al. Infection 45, 479–491; 2017). The researchers suggested that more regulation was needed to prevent further pollution in the region. The pharmaceutical industry in India is not the only source of contamination — pollution is common to many of the country’s cities, and India’s capital, New Delhi, spends its winters wrapped in smog. Krishna Ganesh, director of the Indian Institute of Science Education and Research in Tiruptai, hopes that science can help. “The focus in chemistry is now shifting into areas that involve green and sustainable chemistry,” he says. Research topics include non-toxic chemicals, environmentally benign solvents, organic production and renewable materials. “The main aim should be to get rid of toxic chemicals produced in industrial manufacturing,” and to prevent gases escaping into the atmosphere, he says. Nanotech hopes India’s strength in chemistry has aided its effort to become a leader in the interdisciplinary field of nanotechnology. It’s an especially tempting area of research because there’s a deep vein of funding to mine, says Kizhaeral Subramanian, a researcher in the department of nanoscience and technology at Tamil Nadu Agricultural University in Coimbatore. “Global funding for nanotech had increased from $1 billion in 2000 to $2 trillion in 2016,” he explains. On top of that, Subramanian says that the country has a strong talent pool to draw from owing to the proliferation of nanotechnology degree programmes across the country. From a developmental perspective, the field is a sensible focus as well. As India’s population swells further, the demand for food and clean water is rising. “Nanomaterials can help in water cleansing from bacterial and metal contaminants,” says Ganesh, and nanomaterials may also be able to help with crop protection. For example, Tamil Nadu Agricultural University is researching the production of non-toxic herbicides and fertilizers, as well as emulsions and films that improve the shelf life of fruits and vegetables. Energy dark holes Of India’s 1.3 billion citizens, almost 20% still lack electricity. To help combat this, the country has launched an ambitious renewable-energy plan, broadly focused on solar and wind power. Overall, the country hopes to produce 175 gigawatts from renewable energy sources by 2022 — meeting around 20% of the country’s predicted electricity demand. According to Tata Narasinga Rao, associate director of the International Advanced Research Centre for Powder Metallurgy and New Materials in Hyderabad, India enjoys between 250 and 300 clear sunny days each year — ideal for solar technologies. The energy plan is helped by cheap land, a vast pool of talent to draw from and enthusiastic government support and infrastructure, says Rao. In a review published this year, the International Renewable Energy Agency lists India among the six countries — with Brazil, China, Germany, Japan and the United States — that accounted for most of the renewable-energy jobs in 2016. One research programme, the Solar Energy Research Institute for India and the United States, brings together the Indian Institute of Science in Bangalore and the National Renewable Energy Laboratory in Denver, Colorado, to accelerate the development of solar electric technologies by lowering the cost of production. As part of this venture, scientists developed a new nanotechnological solar absorption system in 2015. The prototype, Rao says, costs half as much as the non-vacuum tubes currently used in solar collectors worldwide and have enormous potential for industry. There are local quirks to take into account before any company starts cashing in on a solar goldmine. Manufacturers still haven’t worked out what to do about monkeys and rats, which relentlessly and indiscriminately chew telephone, electrical and fibre-optic cables across the subcontinent. Meanwhile, Indian researchers are using crop residues, normally burnt as waste by farmers, to develop advanced biofuel systems and products such as biogas and biomaterials. “India’s strong knowledge base in biotechnology, chemistry, engineering and process engineering can be tapped to do research in the biofuel sector,” says Ahmad Kamal, a chemist at the Indian Institute of Chemical Technology in Hyderabad. Calling young scientists back To achieve its grand ambitions, India needs to nurture its new-found brain gain, and is fighting to make itself as attractive as possible through the Department of Science and Technology (DST), one of India’s largest research-funding agencies. In June, for example, the DST announced endowments of $10,000 a month for researchers who choose to move to India from labs overseas. Lipi Thukral, a computational biologist at the Institute of Genomics and Integrative Biology in New Delhi, thinks that the Indian research sector has been unfairly stereotyped abroad. “It is a myth that Indian salaries for scientists are low. They are very good when one factors in the purchasing power of the rupee,” she says. “One can do great science here, too.” Thukral uses high-performance computers to study the movement of biological structures and to model protein folding. After a PhD in Germany, and a postdoc in the UK, she returned to India in 2012 under another DST scheme. Shalini Gupta, a chemical engineer at the Indian Institute of Technology Delhi, returned to India in 2009 after earning a PhD in chemical and biomolecular engineering from North Carolina State University, in Raleigh, and a postdoc from Imperial College London. Gupta’s team is working on cheap, portable medical tools to rapidly diagnose sepsis, a serious complication of many bacterial infections. For her, India makes the perfect laboratory. “We have the advantage of having ready access to patients, samples and field trials.” Meanwhile, the Indian government plans to develop 20 existing universities into ‘world class’ research institutions with an incentive of $1.54 billion of funding. Policymakers hope this will free the country’s best universities from reliance on the country’s grant commission and associated red tape, and encourage greater institutional autonomy. “There are always challenges in working in a third-world country, but India’s role in the development of next-generation technology cannot be ignored, especially in the fields of pharmaceuticals, agriculture, energy and environment,” says Gupta. “If you are situated close to a problem, you have a bigger advantage in terms of solving it.” Nature 552, S41-S43 (2017) doi: 10.1038/d41586-017-07771-y
-
- insight
- Posted 4 months ago
Ageism in Academic Jobs in India
Farah Ishtiaq shares her experience on how age and success are linked in acquiring faculty positions in India India has recently been portrayed as a land of abundant opportunity in academia, investing seriously in research and development to attract skilled scientists. The government has introduced several attractive funding opportunities, with the aim of bringing back scientists working abroad to establish a long-term career here, and improving the overall research infrastructure. Wellcome Trust/DBT India Alliance (WT/DBT) fellowships, for example, have no age or nationality restrictions, relying on qualifications, research experience, career trajectory and the candidate’s determination to establish their own independent research. The WT/DBT India alliance was initiated to develop a large cohort of internationally competitive researchers and help in developing scientific excellence and leadership; a model recently adopted and launched by the Alliance for Accelerating Excellence in Science in Africa (AESA) as well. Since Africa shares a similar burden of healthcare with India, as well as many workplace challenges, Indian scientists are perceived as key collaborators in this mission. There’s a problem here though: age limits on academic positions. Prospective candidates for assistant professor posts in India are preferred by academic institutions to be younger than 35. Although funding bodies are not hiring agencies, the age limit imposed on faculty positions by academic institutions sabotages the driving principle behind these new funding opportunities — the current system is unable to absorb enough competent, experienced scientists. The dilemma for early-career researchers is serious; many fellows are facing this harsh reality and an uncertain future. Every research position has a maximum age limit in India; from a junior research fellow (JRF), with a cut off at 28 years old, to postdoctoral researchers where it is 35 (or 40 years for women). These limits put the Indian academic landscape in stark contrast with many other countries that also follow a tenure-track system. Overall, this makes India a viable option and destination only for scientists of a selected age class. And it certainly gets more complicated for women who want to pursue a career in science and raise a family, with very little allowance made for taking time out for such. I am now in my 40s, which prevents me from being offered an entry-level faculty position. I am also a recipient of a WT/DBT India Alliance fellowship. My funding allowed me to establish an independent laboratory to study the ecology and evolution of emerging infectious diseases in wild bird populations, but despite this incredible research opportunity, I feel my career clock is ticking faster than ever. Getting funding to do science is no longer a problem, but academic policies that prevent competent scientists becoming established are preventing me from succeeding. I feel redundant — surely the quality of my science should be the focus rather than my age? What I would have done differently Hopefully, this should give others like me some insight into avoiding some of the mistakes I made. First, I should have found a trustworthy mentor who could have helped me to navigate my career path. Never put all your eggs in one basket. I should have pitched my grant idea to multiple host institutions to maximise my likelihood of finding an institution that would guarantee a more permanent position by this stage. Do your homework in understanding the system and host academic institution. Even though I deferred my fellowship for a year as my daughter was too little to be left in a crèche, I realise I should have used that time to negotiate or better understand the policy or the institute’s vision for a research fellow like me. Many academic institutions have no guidelines on the role, involvement and career development of academic fellows. Many academics fail to understand the role and potential of fellows like me and often consider them just as an extended postdoc — not as a long-term prospect or potential collaborator. Hence, I did not get enough of an opportunity to teach and to mentor PhD students. Having my own PhD students would have bolstered my career at this stage, and allowed me to evolve as a mentor. Local advice & mindset I’ve received various pieces of advice for improving my faculty application and to enhance my chances of a secure job — this was to publish my current research: i) without foreign authors; and ii) as senior or first author in more prestigious journals such as Science, Nature or PNAS. Whilst the first is possible, the second is easier said than done. Apparently, that was the only thing my CV was missing — a clearer demonstration of my calibre and merit as an independent researcher. Interestingly, for established faculty struggling to earn tenure in India, the culture emphasises quantity of publications rather than quality. And, whilst the second piece of advice (primarily from engineers, cell or molecular biologists) is sound, what was missing was perspective on research in the field of ecology — collecting and publishing groundbreaking ecology data in top journals can take years longer than other disciplines. The journals I have been publishing in are not familiar to some of the members of recruitment panels I’ve met with. I have even been asked if ‘Ibis’ and ‘Parasites & Vectors’ were proper journals. Should India be a role model for developing nations? We are struggling to keep our skilled workers, despite the spending per researcher being equivalent to a developed nation like the UK. I hope other developing countries don’t replicate the above policies, as they certainly don’t help to address some of the major longer-term developmental challenges, including a shortage of researchers. In India, with only 200,000 full time researchers (and only 14% of them women) from a population of 1.3 billion, new research institutes currently being developed end up short of skilled workers and blinkered to new research areas. This all said, I am still very excited. I have a competitive edge and enthusiasm for research where I can play a leading role in high-quality research. Perhaps, it’s time to explore science career options elsewhere, maybe in Africa, and hope no one will question my age?
-
- insight
- Posted 4 months ago
Multidisciplinary Research: Pros and Cons
By bringing together experts from different disciplines we can find the solutions for today’s global challenges. Having spent a year in a multidisciplinary research group, Mit Bhavsar shares his thoughts on the advantages and disadvantages of multidisciplinary research in science. The increasing popularity of mixed scientific disciplines like mechatronics, bioinformatics, biomedical engineering and biophysical chemistry is evidence of the importance of multidisciplinary. And, based on the number of multidisciplinary conferences taking place around the world, it seems that many policymakers agree that bringing scientists from a variety of different backgrounds together is a crucial part of fixing the world’s problems. Going multidisciplinary does not mean leaving behind your own skills — it means heading in new scientific directions using your own specialties. I completed a neurophysiology PhD in a monodisciplinary research group. Now, I’m working as a postdoc in a multidisciplinary research group in the field of regenerative medicine. Here are my perceived advantages and challenges. Advantages One problem I’ve found with a monodisciplinary research group is a lack of creativity when it comes to working out what kind of work can be done. A multidisciplinary group can combine the expertise of your field with other fields and create a varied team. Such combination can lead to creative and high impact research. For example, my lab is working on tissue regeneration and repair through electrical stimuli. For such kind of research, one often needs expertise in the field of medicine and electrical engineering. For me, the most attractive part of multidisciplinary research is that you can work on projects that involve more than one discipline of science. This meant honing my existing skills and learning a whole lot more from scientists I’d never previously had a chance to interact with. As well as that, because I’m the only expert in my field in my group, I can work independently to address problems when they come up. Multidisciplinary research also leads to unusual scientific inventions. A lot of great science has come from the robust interactions of researchers from different fields. A good example of this is the discovery of “Magnetic resonance imaging” by Paul Lauterbur (a chemist) and Peter Mansfield (a physicist) — for this they were awarded the 2003 Nobel prize in Physiology or Medicine. An independent researcher designing and conducting their own separate experiments would never have had these opportunities. Challenges One of the common challenges of working in a multidisciplinary research group is a lack of a “common language.” It’s hard to find a way to start working on a problem when everyone has been trained to approach it from different directions. For me, this makes it difficult to discuss ideas with team members and get the right feedback. This problem feeds into feeling of loneliness — I’m surrounded by lab mates but I’m the only one working on this particular problem in this particular direction in my lab. Another issue: there is no meaningful criticism and evaluation of your work. Your ideas and suggestions are either accepted without any questions or they will be rejected without constructive criticism. If you can deal with these challenges, it can be very rewarding to do multidisciplinary science. To facilitate multidisciplinary research, universities and research institutes should encourage interaction between different disciplines where scientists can meet, share ideas and discuss problems. Mit Bhavsar is a researcher living and working at Frankfurt Initiative for Regenerative Medicine (FIRM) Frankfurt, Germany. You can contact him on: mbhavsa@gwdg.de
-
- conference
- Posted 4 months ago
Down To Earth - Interdisciplinary conference on Agri-Innovation and Entrepreneurship
Between 26 Apr and 26 Apr in Kolkata, India -
- job
- Posted 4 months ago
Assistant Professor
At Kerala Agricultural University in Cochin, India -
- job
- Posted 4 months ago
Junior Research Fellow
At National Institute of Immunology, India in Delhi, India